Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders
Condition(s) studied
Investigational drug(s) / intervention(s)
Submission of the NEO-PI-3 questionnaire: The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).
Submission of the Interpersonal Reactivity Index questionnaire (IRI): The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.
Study summary
Damages in frontal area present in neurodegenerative disease (frontotemporal degeneration, frontal variant of Alzheimer disease) and in psychiatric disease (bipolar disorder) can affect behavior and cognition including social cognition. Symptoms vary both quantitatively and qualitatively from disease to another and from person to person. It cannot be completely excluded that in some cases, factors of susceptibility such as premorbid personality traits lead to frontal fragility.
The study will assess the relationship between premorbid profile using NEO-PI 3 inventory and cognitive and behavioral/psychobehavioral manifestations in patients with behavioral variant of frontotemporal disorder (bvFTD), phenocopy frontotemporal dementia (phFTD), frontal variant of Alzheimer disease, bipolar disorder characterized with frontal damages.
Eligibility
Primary outcome measure(s)
- Premorbid personality traits — Baseline
Premorbid personality traits will be assessed by the NEO- NEO Personality Inventory-3 (NEO-PI-3). The NEO PI-3 measures the five major domains of personality: Neuroticism, Extraversion, Openness to experience, Conscientiousness and Agreeableness. Each domain is defined by 6 facets. NEOPI-3 includes 240 items and responses are made on a 5-point Likert -type scale ranging from strongly Disagree to strongly agree. The NEOPI 3 will be completed by a caregiver who has known the patient in the 10 years preceding the disease onset.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| CHU de Nantes | Nantes | France | Recruiting |
More Nantes University Hospital trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06059313 on ClinicalTrials.gov ↗ ← All trials in France